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Abstract
Currently incurable, prostate cancer metastasis has a remarkable ability to spread to the skeleton. Previous studies
demonstrated that interactions mediated by the cancer-associated Thomsen-Friedenreich glycoantigen (TF-Ag)
and the carbohydrate-binding protein galectin-3 play an important role in several rate-limiting steps of cancer
metastasis such as metastatic cell adhesion to bone marrow endothelium, homotypic tumor cell aggregation,
and clonogenic survival and growth. This study investigated the ability of a synthetic small-molecular-weight non-
toxic carbohydrate-based TF-Ag mimic lactulose-L-leucine (Lac-L-Leu) to inhibit these processes in vitro and, ulti-
mately, prostate cancer bone metastasis in vivo. Using an in vivo mouse model, based on intracardiac injection of
human PC-3 prostate carcinoma cells stably expressing luciferase, we investigated the ability of Lac-L-Leu to
impede the establishment and growth of bone metastasis. Parallel-flow chamber assay, homotypic aggregation
assay, modified Boyden chamber assay, and clonogenic growth assay were used to assess the effects of Lac-L-
Leu on tumor cell adhesion to the endothelium, homotypic tumor cell aggregation, transendothelial migration, and
clonogenic survival and growth, respectively. We report that daily intraperitoneal administration of Lac-L-Leu re-
sulted in a three-fold (P < .05) decrease in metastatic tumor burden compared with the untreated control. Mech-
anistically, the effect of Lac-L-Leu, which binds and inhibits galectins by mimicking essential structural features of
the TF-Ag, was associated with a dose-dependent inhibition of prostate cancer cell adhesion to bone marrow
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endothelium, homotypic aggregation, transendothelial migration, and clonogenic growth. We conclude that small-
molecular-weight carbohydrate-based compounds targeting β-galactoside–mediated interactions could provide
valuable means for controlling and preventing metastatic prostate cancer spread to the skeleton.
Neoplasia (2012) 14, 65–73
Introduction
Despite recent improvements in early detection and treatment, prostate
cancer remains one of the most commonly diagnosed cancers world-
wide and a second leading cause of cancer-related deaths among men
in the United States [1,2]. The prevailing cause of morbidity and
mortality associated with malignant neoplastic disease of the prostate
is metastasis. Advanced prostate cancer almost inevitably metastasizes
to the skeleton [3,4], bringing about devastating complications result-
ing in spinal cord compression, intractable pain, and, ultimately, death.
At present, there is no effective means to control or prevent metastatic
dissemination of hormone refractory prostate cancer.
Hematogenous spread of prostate cancer is an extremely complex
process regulated on many levels and involving multiple rate-limiting
steps [5–7]. Previous results from our group and those of others
demonstrated that several critical steps in hematogenous cancer metas-
tasis, including prostate cancer, are regulated in part by β-galactoside–
mediated interactions involving cancer-associated Thomsen-Friedenreich
carbohydrate antigen (TF-Ag) and β-galactoside–binding lectin galectin-3
(Gal-3). Specifically, Gal-3 was implicated in prostate cancer cell pref-
erential adhesion to bone marrow endothelial cells [8]. TF-Ag/Gal-3
interactions were shown to mediate the adhesion of metastatic cells
to the endothelium [9–16], homotypic cancer cell aggregation at the
sites of primary attachment to the endothelium [13,17], the in vivo
formation of intravascular metastatic deposits in lungs and bones of
experimental animals after intravenous inoculation [12,16], as well as
clonogenic survival and growth of metastatic cancer cell lines [17–19].
Importantly, all these processes representing critical rate-limiting steps
in cancer metastasis could be inhibited efficiently using carbohydrate-
based compounds blocking galectins by mimicking essential structural
features of their natural ligands [9,19–22].
The concept of using carbohydrate-based galectin inhibitors for
targeting cancer metastasis has been conceived by early pioneering
works from the group of Dr Raz [23–25]. Subsequent discovery of
Gal-3 functioning in various pathologic and physiological processes
such as cell adhesion [26–29], angiogenesis [30,31], and regulation
of apoptosis [32] attracted increasing attention of the research com-
munity, resulting in the development of carbohydrate-based galectin
inhibitors by several different groups [33–39]. One such inhibitor,
modified citrus pectin (MCP) developed by the group of Dr Raz
[23–25], has been shown to inhibit experimental metastasis in vivo
in several animal models, notably mouse B16 melanoma [23,24], rat
MAT-LyLu prostate carcinoma [25], human MDA-MB-435 breast
carcinoma [20], and human LSLiM6 colon carcinoma [20].
Another carbohydrate-based galectin inhibitor developed by this
group, the synthetic β-galactoside disaccharide/amino acid conjugate,
glycoamine lactulose-L-leucine (Lac-L-Leu), binds and inhibits Gal-3
by mimicking cancer-associated TF-Ag [9,10,17]. This compound’s
TF-Ag–mimicking properties were confirmed through inhibition of
TF-Ag/polyacrylamide conjugate binding to cancer cells, blocking
binding of TF-Ag–specific PNA lectin to asialofetuin, and inhibiting
Gal-3 interactions with TF-Ag conjugated to human serum albumin
[9]. Consequently, Lac-L-Leu has been shown to impede in vitro and
ex vivo heterotypic (between tumor and endothelial cells) and homo-
typic (between tumor cells) metastasis-associated tumor cell adhesive
interactions includingDU-145 human prostate cancer cells [9,10,12–17],
the in vivo formation of early metastatic deposits in lungs and bones by
human breast (MDA-MB-435) and prostate (DU-145) cells [12,16],
the in vitro clonogenic survival and growth of several different types
of cancer [17–19], and ultimately MDA-MB-435 and MDA-MB-
435Lung2 human breast carcinoma spontaneous lung metastasis in
nude mice [19,22]. To date, however, carbohydrate-based galectin in-
hibitors have not been tested yet in vivo against human prostate cancer
bone metastasis.
In this study, we used the in vivo bone metastasis model based on
the intracardiac injection of PC-3Luc cells [40] to investigate the
ability of Lac-L-Leu to affect the establishment and development of
prostate cancer metastatic bone lesions. We report that daily treat-
ment of experimental animals with nontoxic carbohydrate-based
small-molecular-weight galectin inhibitor Lac-L-Leu without any
addition of cytotoxic drugs resulted in a three-fold inhibition of pros-
tate cancer bone metastasis. Mechanistically, the Lac-L-Leu effects
were associated with the inhibition of prostate cancer cell adhesion
to bone marrow endothelium, their homotypic aggregation, trans-
endothelial migration, as well as clonogenic survival and growth, sug-
gesting that this compound affects both the establishment and the
early development of prostate cancer bone metastasis.
Materials and Methods
Chemicals and Reagents
Synthetic glycoamines lactulose-L-leucine (Lac-L-Leu; N -(1-deoxy-
4-O-(β-D-galactopyranos-1-yl)-D-fructos-1-yl)-(S )-2-amino-4-methyl-
pentanoic acid) and lactitol-L-leucine (Lct-L-Leu;N -(1-deoxy-4-O-(β-D-
galactopyranos-1-yl)-D-glucitol-1-yl)-(S )-2-amino-4-methylpentanoic
acid) were synthesized as previously described [21]. All other chemicals
and reagents, unless otherwise specified, were purchased from Sigma
(St Louis, MO).
Cell Lines and Cultures
PC-3Luc cell line was developed previously using stable transfection
of metastatic human prostate carcinoma PC-3 (ATCC, Rockville,
MD) with luciferase-expressing pLazarus retroviral vector [40]. The
DU-145 human prostate carcinoma cells were purchased from ATCC.
Tumor cell lines were routinely maintained on plastic as monolayer
cultures using RPMI-1640 medium supplemented with 10% fetal
bovine serum (FBS) in a 5% CO2 humidified incubator. The develop-
ment of human bonemarrow endothelial cell line HBME-1, which was
used in parallel-flow chamber experiments, was described previously
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[8]. HBME-1 cells were cultured in Dulbecco modified Eagle medium
supplemented with L-glutamine, 10% FBS, and sodium pyruvate.
In Vivo Bioluminescent Model of Metastatic Prostate
Cancer Growth
Animal experiments were conducted according to the University of
Michigan’s Institutional Animal Care and Use Committee approved
protocol. Briefly, 5- to 6-week-old male severe combined immuno-
deficient mice (n = 30) purchased from Charles River (Wilmington,
MA) were randomly divided into three groups (n = 10 animals per
group). In all three groups, PC-3Luc cells (2 × 105 cells in 100 μl
of Dulbecco phosphate-buffered saline [PBS] lacking Ca2+ and Mg2+)
were introduced into animals by intracardiac injection under 1.75%
isoflurane/air anesthesia. Throughout the duration of the experiment,
animals in group 1 were receiving daily 20 μM of Lac-L-Leu adminis-
tered intraperitoneally (i.p.) in 0.2 ml of sterile physiological saline
beginning 1 week before tumor cell inoculation. In group 2, animals
were receiving 20 μM of Lac-L-Leu daily administered i.p. in 0.2 ml
of sterile physiological saline beginning 1 week after tumor cell inocula-
tion. In group 3 (untreated control), animals were receiving daily 0.2 ml
i.p. injection of the vehicle, sterile physiological saline. Bioluminescent
imaging of PC-3Luc was performed as previously described [40,41]
through the University of Michigan Small Animal Imaging Resource
facility.Mice were serially imaged weekly for 5 weeks using a CCD IVIS
system with a 50-mm lens (Xenogen Corp, Alameda, CA), and the re-
sults were analyzed using Living Image software (Xenogen). For imaging,
mice were injected with luciferin (40 mg/ml) i.p., and ventral images
were acquired 15 minutes after injection under 1.75% isoflurane/air
anesthesia. For each animal, total tumor burden was calculated using re-
gions of interest. At the end of the experiments, animals were killed, and
tissue was collected for histopathologic confirmation of bone metastasis.
In Vitro Parallel-Flow Chamber Assay
The adhesion of PC-3Luc and DU-145 cells to the monolayers of
human bone marrow endothelial cells was studied in an in vitro parallel-
plate laminar flow chamber as follows. HBME-1 cells were grown until
100% confluent in 35-mm tissue culture dishes coated overnight with
poly-L-lysine (10 μg/ml) at 4°C. The parallel-plate flow chamber deck
with a 100-μm gasket (Glycotech, Rockville, MD) was assembled over
the endothelial monolayer, and endothelial cells were exposed to flow
conditions (0.8 dyn/cm2 shear stress) by perfusing warm medium
(RPMI-1640 containing 0.75 mM Ca2+ and Mg2+ and 0.2% human
serum albumin) using a constant infusion/withdrawal syringe pump
(KDS210;KD Scientific, NewHope, PA).Next, a single-cell suspension
of cancer cells (5 × 104 cells/ml) was perfused for a 15-minute period in
the presence or absence of 200 μM of synthetic glycoamines (Lac-L-Leu
or Lct-L-Leu). Tumor cell interactions with HBME-1 monolayers were
observed by using an inverted phase-contrast Diavert microscope (Leitz,
Wetzlar, Germany) and video recorded in three different observation
fields (5 minutes per field) for subsequent frame-by-frame analysis.
The number of rolling cells and the number of stably adherent cells
per field were determined during 1- and 5-minute periods, respectively,
in at least three different observation fields for each experimental setting.
Data are presented as means ± SD.
Homotypic Aggregation Assay
The effect of various concentrations (0-1.0 mM) of the Lac-L-Leu
and Lct-L-Leu on PC-3Luc prostate carcinoma cell spontaneous aggre-
gation was assessed using a homotypic aggregation assay as previously
described [13,22]. Briefly, cells were detached from the tissue culture
plates with PBS containing 2 mM EDTA, washed with PBS, and re-
suspended to a density of 1 × 106 cells/ml in serum-free RPMI 1640
media. Next, tumor cell suspension (500 μl containing 5 × 105 cells)
was mixed with 500 μl of serum-free medium in the presence of
increasing concentrations (0-1.0 mM final concentration) of the Lac-L-
Leu or the control glycoamine Lct-L-Leu. Plastic tubes containing can-
cer cells were placed in a rotator and agitated for 1 hour at 37°C. After
the incubation, three 25-μl aliquots from each sample were spotted
onto a microscope slide and dried for 1 hour at room temperature.
The slides were fixed overnight in a closed container with 37% form-
aldehyde in a bottom reservoir. Immediately before microscopic evalu-
ation, 25 μl of PBS was placed onto each spot to facilitate viewing. The
total number of cells and the number of cells in aggregates were
counted in four random fields. The percent of cells in aggregates (num-
ber of cells in aggregates / total number of cells × 100) and the average
number of aggregated cells were calculated for individual samples. Each
assay was performed in triplicate. Results are presented as means ± SD.
Transendothelial Migration
Endothelial cells (2 × 104) were seeded into the 24-well collagen
type I–coated Biocoat cell culture inserts (Becton Dickinson, Bedford,
MA) with 3-μm-pore-size track-etched PETmembranes permitting cell
viewing by light microscopy and were grown for 5 days until fully con-
fluent. Next, 1 × 104 of GFP-tagged PC-3 or DU-145 cells were added
to each well in 5% FBS medium with or without compound tested and
allowed to interact overnight while using 20% FBS medium in the
lower chamber as a chemoattractant. The next day, the cells in the
upper chamber were gently wiped with cotton swab, and the transmi-
grated cells were photographed on a lower surface of the membrane
using an epifluorescent microscope. Images of four fields (1 field for
each quadrant of the membrane) were acquired using a 10× lens.
The assays were performed in quadruplicate for each experimental set-
ting, and results are presented as means ± SD.
Clonogenic Survival and Growth
The PC-3Luc or DU-145 cells, grown until 50% to 60% conflu-
ent, were harvested using a nonenzymatic cell dissociation reagent as
described above and plated at a low density in quadruplicate (100 and
200 viable cells per well) in a 24-well culture plate without (control) or
in the presence of compounds tested. Only cells with a viability of 95%
or greater were used. Seven days later, the cells were fixed with 1%
formaldehyde in PBS and stained with hematoxylin, and colonies of
more than 15 cells were scored.
Statistical Analysis
The 2-tailed paired Student’s t test or one-way analysis of variance
(for multiple group comparison) was used to assess statistical signif-
icance of the results. χ2 analysis was used to compare metastatic tumor
burden distribution between the groups. The difference between the
groups was considered significant at P ≤ .05.
Results and Discussion
Lac-L-Leu Inhibits PC-3Luc Bone Metastasis In Vivo
Prostate cancer bone metastasis model based on intracardiac injec-
tion of PC-3Luc cells is perhaps the only currently available model
recapitulating both hematogenous steps involved in prostate cancer
metastatic spread and many of the clinical features of prostate cancer
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metastasis [40]. Owing to a constitutive expression of firefly luciferase
in PC-3Luc cells, this experimental system allows for a nondestructive
quantitative imaging of metastatic lesions (Figure 1A) to monitor tem-
poral dynamics of disease progression and effects of therapeutic inter-
ventions in individual animals (Figure 2A). A detailed postmortem
histopathologic examination performed at the end of the experiment
confirms the presence of metastatic tumor cells in the skeletal lesions
(Figure 1, B-D). Of note, although metastatic tumor burden in this
model is mostly associated with bone colonization, soft tissue (adrenal
gland, liver, lung, and lymph node) metastases could be observed as
well [40]. However, because the focus of this study was on bone metas-
tasis, we only confirmed histopathologically metastatic lesions detected
by bioluminescent imaging in femoral, tibial, mandibular, and nasal
bones of experimental animals and did not perform soft tissue histology.
In the current study, we used this experimental system to investi-
gate effects of the TF-Ag mimic, synthetic carbohydrate-based Gal-3
inhibitor Lac-L-Leu, on the establishment and growth of PC-3Luc
bone metastasis. In these experiments, the animals were divided into
three groups receiving systemic treatment as follows: Lac-L-Leu begin-
ning 1 week before tumor cell inoculation (group 1), Lac-L-Leu begin-
ning 1 week after tumor cell inoculation (group 2), vehicle (sterile
physiological saline) only (group 3/control). In all three groups, the
animals were imaged weekly throughout the duration of the study
(up to 4 weeks after tumor cell injection) beginning from the day of
tumor cell inoculation.
The results of these experiments (Figure 2) demonstrated the
strongest beneficial effect for Lac-L-Leu administered to the mice
beginning 1 week before PC-3Luc cell inoculation (group 1), com-
pared with the postinoculation treatment (group 2) or the untreated
control (group 3). On the basis of the photon counts, temporal dynam-
ics of metastatic tumor burden in individual animals between the
groups has been clearly separated as follows: group 1 < group 2 < control
(Figure 2A). At week 4 after tumor cell injection, metastatic tumor
burden in group 1 animals was approximately three-fold (P < .05) less
than in control (Figure 2B). In group 2, however, because three animals
were lost early in the experiment to unknown causes, the number of
mice was reduced to n = 7. Consequently, the difference between aver-
age photon counts in group 2 and control did not reach statistical sig-
nificance because of insufficient power (Figure 2B). However, χ2
analysis ofmetastatic tumor burden distribution within the groups dem-
onstrates that both groups 1 and 2 indeed differed significantly from
the control (Table 1).
Furthermore, groups 1 and 2 also differ significantly from each other
(P = .05, t-test; P = .0168, χ2 test). The more pronounced protective
effect of Lac-L-Leu against PC-3Luc bone metastasis in group 1 (in
which treatment commenced 1 week before tumor cell injection) com-
pared with group 2 (in which treatment commenced 1 week after tumor
cell inoculation) and untreated control indicates that the compound
inhibits both the process of metastatic lesion establishment and the
growth of early metastatic colonies. Thus, we investigated next how
Lac-L-Leu affects prostate cancer cell metastasis–associated heterotypic
(with bone marrow endothelial cells) and homotypic (with each other)
adhesive interactions, their transendothelial migration, as well as clono-
genic survival and growth.
Figure 1. Intravital bioluminescent imaging of PC-3Luc metastatic burden and subsequent postmortem histopathologic confirmation of
skeletal metastases. (A) An example of the bioluminescent imaging using a CCD IVIS system showing PC-3Luc metastatic tumors to the
limbs, jaws, and ribs. Two animals from the control group are shown at week 3 after tumor cell injection. A color scale reflecting photon
count in pseudocolored images is shown on the left. (B-D) Histopathologic confirmation and analysis of skeletal metastases. (B) Photo-
micrograph of PC-3Luc bone metastasis (hematoxylin and eosin, decalcified; original magnification, ×10). A tumor mass (T) is present
in the marrow cavity, as well as smaller tumor cell clusters (T + arrow) in the cortical bone (B). (C and D) Osteoclast-like cells (OC),
commonly associated with bone metastases, are present at the interface between the tumor (T) and the cortical bone (B) (hematoxylin
and eosin, decalcified; original magnification, ×10 [C] and ×40 [D]).
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Lac-L-Leu Inhibits PC-3Luc and DU-145
Metastasis-Associated Adhesive Interactions
Previous studies demonstrated that TF-Ag/Gal-3–mediated inter-
actions support both metastatic cell adhesion to the endothelium and
their homotypic aggregation at the sites of primary attachment to the
vascular wall [9–17]. Therefore, we have used a parallel-flow chamber
assay to investigate the effect of TF-Ag mimic Lac-L-Leu on PC-3Luc
and DU-145 adhesive interactions with monolayers of HBME-1
human bone marrow endothelial cells under conditions of physiological
(0.8 dyn/cm2) wall shear stress. Another synthetic glycoamine Lct-L-
Leu, which is an inactive isomer of Lac-L-Leu [9], was used as a negative
control in these experiments. The results of the parallel-flow chamber
experiments (Figure 3A) demonstrated that Lac-L-Leu inhibited PC-
3Luc and DU-145 cell rolling onHBME-1monolayers 3.5- to 4.5-fold
(P < .05) and stable adhesion 11.5-fold (P < .01), respectively. In con-
trast, Lct-L-Leu failed to inhibit prostate cancer cell adhesive inter-
actions with endothelial cells. Similarly, Lac-L-Leu (but not Lct-L-Leu)
inhibited PC-3Luc and DU-145 homotypic aggregate formation in a
dose-dependent manner (Figure 3, B and C ). These results indicate
that Lac-L-Leu efficiently inhibits intravascular metastasis–associated
prostate cancer cell adhesive interactions. In addition, the fact that
Lac-L-Leu, but not Lct-L-Leu, exhibits inhibitory activity toward PC-
3Luc metastasis–associated interactions indicates that this property of
the compound depends entirely on its carbohydrate moiety and apti-
tude to mimic TF-Ag. The only difference between lactulose and lac-
titol is that glucose in the latter disaccharide is in the open (alcohol)
form. However, this modification abolishes inhibitory properties of
the compound owing to a nearly complete lack of lactitol affinity to
Gal-3 [42].
Lac-L-Leu Inhibits PC-3Luc and DU-145 Transendothelial
Migration and Clonogenic Growth
Next, we investigated whether blocking TF-Ag/Gal-3–mediated
interactions with Lac-L-Leu affects subsequent steps of the metastatic
Figure 2. The effect of Lac-L-Leu treatment on PC-3Luc bone metastasis. (A) Temporal dynamics of changes in metastatic tumor burden
in individual animals from group 1 (daily Lac-L-Leu treatment commenced 1 week before tumor cell injection), group 2 (daily Lac-L-Leu
treatment commenced 1 week after tumor cell injection), and control during the 4 weeks after intracardiac tumor cell inoculation as
revealed by biophoton count. (B) Cumulative data showing average metastatic tumor burden in each experimental group at week 4 after
tumor cell inoculation. Data are presented as means ± SEM. (C) Representative images of animals from each experimental group at
4 weeks after tumor cell injection.
Table 1. χ2 Analysis of Metastatic Tumor Burden Distribution within Experimental Groups Based
on Biophoton Count.
Threshold 1 (2 × 108 Photon
per Second)
Threshold 2 (3 × 108 Photon
per Second)
Percent above Threshold P (χ2) Percent above Threshold P (χ2)
Group 1 30% (3/10) <.0001 20% (2/10) <.0001
Group 2 71% (5/7) .0433 43% (3/7) .014
Control 100% (10/10) 80% (8/10)
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cascade such as tumor cell transendothelial migration and their
clonogenic survival and growth. We have used transwell migration
assay to assess the effect of Lac-L-Leu and Lct-L-Leu on the ability
of prostate cancer cells to traverse endothelial monolayers. The results
of these experiments (Figure 4, A and B) demonstrated that Lac-L-Leu,
but not Lct-L-Leu, efficiently inhibited PC-3 and DU-145 cell migra-
tion through the monolayers of endothelial cells (P < .01). The com-
pound also inhibited clonogenic survival and growth of PC-3Luc and
DU-145 cells in a dose-dependent manner (Figure 4C ).
In summary, our in vitro experiments show that synthetic TF-Ag
mimic Lac-L-Leu is inhibiting prostate cancer cell adhesive interac-
tions with endothelial cells (rolling and stable adhesion), the forma-
tion of tumor cell multicellular aggregates (homotypic aggregation),
transendothelial migration, and clonogenic survival and growth, in-
dicating that TF-Ag–mediated interactions are involved in multiple
aspects of prostate cancer metastasis to the skeleton. In vivo, these
effects translate onto intravascular metastasis-associated events (initial
metastatic cell arrest in distant organ microvasculature), tumor cell
extravasation, and survival and growth of early metastatic colonies.
This explains the difference in the therapeutic effects achieved by
Lac-L-Leu in two treatment groups. That is, the more pronounced
effect in group 1 (daily Lac-L-Leu therapy commenced 1 week before
tumor cell injection) was associated with the inhibitory effects on
both the establishment and the development of early metastatic col-
onies, whereas in group 2 (daily Lac-L-Leu therapy commenced 1 week
after tumor cell injection), only the effect on survival and clonogenic
growth of micrometastases was present.
For a proper understanding of the mechanisms of action of Lac-L-Leu,
it is important to recognize that the compound targets Gal-3 in different
cell types and locations to inhibit different metastasis-associated pro-
cesses (Figure 5). Previously, we demonstrated that TF-Ag induces
Gal-3 translocation to the outer cell membranes in both endothelial
and cancer cells [9,15,17] and then uses it as a binding partner to
mediate heterotypic and homotypic adhesion respectively [9,15,17].
Thus, heterotypic adhesive interactions between tumor and endothelial
cells (Figure 5A) are inhibited by Lac-L-Leu through blocking Gal-3
Figure 3. Inhibition of PC-3Luc and DU-145 metastasis-associated adhesive interactions by Lac-L-Leu. (A) Synthetic TF-Ag mimic Lac-L-
Leu, but not Lct-L-Leu, inhibited PC-3Luc (open bars) and DU-145 (closed bars) rolling on (left panel) and stable adhesion (right panel) to
HBME-1 human bone barrow endothelial cell monolayers under conditions of physiological flow. (B and C) Synthetic TF-Ag mimic Lac-L-
Leu inhibited PC-3Luc (left panel) and DU-145 (right panel) tumor cell homotypic aggregation in a dose-dependent manner (B), whereas
its inactive isomer Lct-L-Leu failed to inhibit the formation of prostate cancer cell multicellular aggregates (C). The experiments in A and C
were performed using 200 μM (final concentration) of the compounds tested. *P < .05, **P < .001.
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translocated to the endothelial cell surfaces in response to TF-Ag
[9,15,17]. Consequently, this inhibitory effect of Lac-L-Leu does not
depend on the expression of Gal-3 in tumor cells. To inhibit the for-
mation of homotypic tumor cell aggregates (Figure 5B ), Lac-L-Leu
binds and blocks Gal-3 clustered on the outer cell membranes of cancer
cells [10,17]. Thus, the inhibitory effects of Lac-L-Leu on heterotypic
and homotypic metastatic cell adhesive interactions occur through a
direct competitive blockage of TF-Ag interactions with Gal-3 localized
to the endothelial (Figure 5A) and tumor (Figure 5B ) cell surfaces,
respectively. In contrast, the effect of the compound on metastatic cell
clonogenic survival and growth is due at least in part to the inhibition of
intracellular Gal-3 antiapoptotic function on mitochondrial apoptosis
pathway (Figure 5C ). In our previous studies, we demonstrated that,
in a process of clonogenic survival, most metastatic tumor cells die from
Figure 4. Inhibition of prostate cancer cell transendothelial migration and clonogenic growth by synthetic TF-Ag mimic Lac-L-Leu. (A and
B) Synthetic TF-Ag mimic Lac-L-Leu, but not its inactive isomer Lct-L-Leu, inhibited PC-3 and DU-145 cell transendothelial migration
in vitro in transwell chamber experiments. (C) Dose-dependent inhibition of PC-3Luc (left panel) and DU-145 (right panel) cell clonogenic
survival and growth by synthetic glycoamine Lac-L-Leu. *P < .05, **P < .001.
Figure 5. Lac-L-Leu mechanisms of action. (A) Heterotypic adhesive interactions between endothelial and cancer cells are inhibited
through Lac-L-Leu binding to Gal-3 on endothelial cell surfaces preventing its interactions with TF-Ag presented on tumor cells. (B) Inhibition
of tumor cell homotypic aggregation is achieved by blocking Gal-3 clustered on cancer cell outer membranes. (C) Inhibition of intracellular
Gal-3 antiapoptotic function on mitochondrial apoptosis pathway reduces metastatic cell clonogenic survival.
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apoptosis [18,19], executed through intrinsic, mitochondrial pathway
[19], and Lac-L-Leu enhances tumor cell apoptotic death by inhibiting
Gal-3 antiapoptotic function [19]. Among carbohydrate-based galectin
inhibitors, the ability to block Gal-3 antiapoptotic function and sup-
press tumor cell clonogenic survival is not unique to Lac-L-Leu.
MCP also efficiently inhibits tumor cell clonogenic survival by blocking
Gal-3 antiapoptotic function [18]. Thus, both antiadhesive properties
of carbohydrate-based galectin inhibitors and their ability to inhibit
Gal-3 antiapoptotic function could be used to target the establishment
and development of metastatic lesions. Moreover, because of the im-
portant role played by Gal-3 in regulating tumor cell apoptosis (re-
viewed in Nakahara et al. [32]), the ability of carbohydrate-based
galectin inhibitors to impede Gal-3 antiapoptotic function on the
mitochondrial pathway could be exploited further to increase the effi-
cacy of cytotoxic therapies [18,19,32,43,44]. Indeed, inhibition of
Gal-3 antiapoptotic function by MCP (also known as GCS-100)
was sufficient to reverse multiple myeloma cell resistance to bortezomib
and enhance their response to apoptosis induced by dexamethasone
[45], cause 10.7-fold reduction of doxorubicin IC50 in vitro against
hemangiosarcoma cells [18], and increase PC-3 cell sensitivity to
cisplatin-induced apoptosis [46]. Similarly, blocking Gal-3 antiapopto-
tic function using Lac-L-Leu resulted in a 7.0-fold decrease in taxol
IC50 in vitro against breast carcinoma cells [19] and in a 3.6-fold
decrease in doxorubicin IC50 in vitro against hemangiosarcoma cells
[18] and caused eradication of advanced metastatic disease in vivo
in 56% of experimental animals with established breast cancer metas-
tases treated with the Lac-L-Leu/paclitaxel combination [19]. Thus, it
seems that the most promising clinical use of this class of compounds
would be not only as single agents to block metastasis-associated ad-
hesive events but also in combination with cytotoxic drugs to aug-
ment their effect on metastatic disease. Furthermore, such combination
therapy regimens could be tailored to target metastatic cells when they
still reside within intravascular compartment [47] as well as against
circulating tumor cells.
In conclusion, it is quite remarkable that a simple nontoxic carbohydrate-
based compound is capable of inhibiting three-fold metastatic burden
associated with prostate cancer spread to the skeleton without addition
of any cytotoxic drugs. In addition to Lac-L-Leu, other carbohydrate-
based galectin inhibitors have been reported in the literature by differ-
ent groups [33–39]. The results presented in this study suggest that this
class of compounds holds strong potential of being developed into a
valuable addition to the armamentarium of antimetastatic agents for
controlling prostate cancer spread to the skeleton.
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